Adoptive immunotherapy of advanced solid tumors: An eight year clinical experience

Anticancer Research

Volumn 19, Issue 6 C, 1999, Pages 5645-5649

  Semino, Claudia ^a   Martini, Laura ^c   Queirolo, Paola ^a   Cangemi, Giuliana ^a   Costa, Roberta ^b   Alloisio, Antonella ^b   Ferlazzo, Guido ^a   Sertoli, Mario Roberto ^b   Reali, Umberto M ^c   Ratto, Giovanni Battista ^b   Melioli, Giovanni ^a,d  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Adoptive immunotherapy; Cytokines; Lymphokine activated killer cells; Melanoma; Non small cell lung cancer; Tumor infiltrating lymphocytes

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; GOOD LABORATORY PRACTICE; HUMAN; KIDNEY CARCINOMA; LIVER CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; MELANOMA; MESOTHELIOMA; META ANALYSIS; PRIORITY JOURNAL; SOLID TUMOR;

CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); SURVIVAL RATE;

EID: 0033367023     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Grimm EA, Mazumder A, Zhang-HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823-41, 1982.
2. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-21, 1986.
3. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889-97, 1987.
4. Rosenberg SA, Packard BS, Aebersold PM et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319: 1676-80, 1988.
5. Dillman RO, Oldham RK, Barth NM et al: Continuous interleukin-2 and tumor infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer 68: 1-8, 1991.
6. Ravaud A, Legrand E, Dalaunay MM, et al: A phase 1 trial of repeated tumor infiltrating lymphocytes (TIL infusions in metastatic melanoma. Br J Cancer 71: 331-6, 1995.
7. Goedegebuure PS, Douville LM, Li H, et al: Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 8: 1939-49, 1995.
8. Melioli G, Ratto GB, Guastella M, et al: Isolation and in vitro expansion of lymphocytes infiltrating non-small cell lung carcinoma: functional and molecular characterization for their use in adoptive immunotherapy. Eur J Cancer 30: 97-102, 1994.
9. Melioli G, Guastella M, Semino C et al: Proliferative, phenotypic, functional and molecular characteristics of tumor infiltating lymphocytes, obtained from unselected patients with malignant melanomas and expanded in vitro in the presence of rIL-2. Melanoma Res 4: 127-33, 1994.
10. Ferlazzo G, Scisca C, Iemmo R et al: Intralesional sonographically guided injections of lymphokine activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study. J Immunotherapy 20: 158-63, 1997.
11. Mountain CF: Revisions in the International System for Staging Lung Chest 111(6): 1710-7, 1997.
12. Gershenwald JE, Buzaid AC, Ross MI: Classification and staging of melanoma. Hematol Oncol Clin North Am Aug 12(4): 737-65, 1998.
13. Ponte M, Queirolo P, Semino C, et al: Analysis of the proliferative and phenotypic properties of tumor infiltrating lymphocytes expanded in vitro in the course of the clinical trial of adoptive immunotherapy of metastatic melanoma. Oncol Rep 4: 27-31, 1997.
14. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith T, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14(1): 7-17, 1996.
15. Kimura H and Yamaguchi Y: A phase II randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or non curative resection of primary lung carcinoma. Cancer 80: 42-9, 1997.
16. Reali UM, Martini L, Borgognoni L, et al: Infusion of in vitro expanded tumor infiltrating lymphocytes (TIL and recombinant interleukin-2 in patients with surgically resected lymph node metastases of malignant melanoma: a pilot study. Melanoma Res 8: 77-82, 1998.
17. Queirolo P, Ponte M, Gipponi M, et al: Adoptive Immunotherapy With Tumor-Infiltrating - Lymphocytes (TIL) And Subcutaneous Recombinant Interleukin-2 plus Interferon alpha 2a in Melanoma Patients with Not Resectable Distant Disease. A Phase I-II Pilot Trial. Ann Surg Oncol. (in press).
18. Ratto GB, Melioli G, Fantino G et al: Limmunoterapia adottiva nel trattamento del carcinoma polmonare non a piccole cellule in fase avanzata. Chirurgia 8: 140-3, 1995.
19. Ratto GB, Melioli G, Zino P, et al: Immunotherapy using tumor-infiltrating lymphocytes and Interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer. A pilot study. J Thor Cardiovasc Surg 105: 1212-7, 1995.
20. Melioli G, Ratto GB, Ponte M, et al: Treatment of Stage IIIb non small cell lung cancer with surgery followed by infusion of Tumot Infiltrating Lymphocytes and Recombinant Interleukin-2: a pilot study. J Immunother 19: 224-30, 1996.
21. Ratto GB, Zino P, Mirabelli S, et al: A randomized trial of adoptive immunotherapy with tumor infiltrating lymphocytes and interleukin-2 vs. standard therapy in the postoperative treatment of resected non-small-cell lung cancer. Cancer 78: 244-51, 1996:
22. Ratto GB, Cafferata M, Scolaro T, et al: A phase II study of combined immunotherapy, chemotherapy and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer. J Immunother, (in press).